| Title |
Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma
|
|---|---|
| Published in |
European Journal of Clinical Pharmacology, November 2011
|
| DOI | 10.1007/s00228-011-1152-y |
| Pubmed ID | |
| Authors |
Rabindra Kumar Jena, Trupti Rekha Swain, Sandeep Sadashivrao Kansurkar, Manorama Swain |
| Abstract |
The chemotherapeutic regimen melphalan, prednisolone, and thalidomide (MPT) is the standard of care for symptomatic multiple myeloma patients who are not eligible for high dose chemotherapy followed by autologous stem cell therapy. Lenalidomide, a newer thalidomide derivative, is 300 times more potent than thalidomide. Combined therapy using melphalan, prednisolone, and lenalidomide (MPL) is very effective with many advantages. We report here one rare adverse effect, i.e., intrahepatic cholestasis related to lenalidomide, in two patients out of a total of 65 newly diagnosed cases of multiple myeloma receiving MPL regimen in our series. As the use of lenalidomide will increase in the future for multiple myeloma and other diseases, clinicians should be aware of this entity. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 21% |
| Student > Master | 3 | 21% |
| Researcher | 2 | 14% |
| Student > Ph. D. Student | 2 | 14% |
| Student > Bachelor | 1 | 7% |
| Other | 0 | 0% |
| Unknown | 3 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 50% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 21% |
| Nursing and Health Professions | 1 | 7% |
| Unknown | 3 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2011.
All research outputs
#18,301,870
of 22,659,164 outputs
Outputs from European Journal of Clinical Pharmacology
#2,212
of 2,548 outputs
Outputs of similar age
#195,514
of 239,722 outputs
Outputs of similar age from European Journal of Clinical Pharmacology
#20
of 27 outputs
Altmetric has tracked 22,659,164 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,548 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 239,722 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.